Form 4: Ligand Pharmaceuticals Director Exercises Options and Sells Shares

Director John L. LaMattina exercised stock options and sold shares of Ligand Pharmaceuticals on November 27, 2024.

Summary

• On November 27, 2024, John L. LaMattina, a director at Ligand Pharmaceuticals, exercised 2,406 stock options at a price of $52.30 per share.
• Following the exercise of these options, Mr. LaMattina sold 2,406 shares of common stock at a price of $123.65 per share.
• After these transactions, Mr. LaMattina directly owns 29,515 shares of Ligand Pharmaceuticals common stock.

Sentiment

Score: 5

Explanation: The document is a neutral report of insider trading activity, with no inherent positive or negative sentiment.

Industry Context

This is a routine disclosure of insider trading activity, which is common for publicly traded companies. It provides transparency into the transactions of company directors.

Comparison to Industry Standards

• The reporting of stock option exercises and share sales by directors is a standard practice for publicly traded companies, as mandated by the SEC.
• Similar filings are regularly made by directors and officers of companies like Amgen (AMGN), Gilead Sciences (GILD), and Regeneron Pharmaceuticals (REGN), reflecting their transactions in company stock.

Stakeholder Impact

• The transaction has a minor impact on shareholders as it reflects a director's personal financial decisions.

Key Dates

Keywords

Ligand Pharmaceuticals, stock options, insider trading, share sale, director, LGND